title: Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta.
abstract: Toll-like receptors (TLR) are believed to play a major role in the recognition of invading organisms, although their ability to shape immune responses is not completely understood. Our aim was to investigate in vivo the effect of different TLR stimuli on the generation of antibody responses and the induction of CD8+ T-cell cross-priming after immunization with soluble protein antigens. While all TLR agonists tested elicited the production of immunomodulatory cytokines, marked differences were observed in their ability to stimulate antigen-specific immune responses. Zymosan, poly(I:C) and CpG DNA, which signal through TLR2/6, 3 and 9, respectively, were found to strongly induce the production of IgG2a antibodies, whereas R-848 (TLR7) and LPS (TLR4) did so much more weakly. In contrast, LPS, poly(I:C) and CpG DNA, but not zymosan, induced functional CD8+ T-cell responses against OVA; peptidoglycan (TLR2/?) and R-848 were also ineffective in stimulating cross-priming. Experiments using IFN-alpha/beta R-deficient mice showed that the induction of cross-priming by LPS and poly(I:C) was abrogated in the absence of IFN-alpha/beta signalling, and induction by CpG DNA was greatly reduced. Overall, our results identify LPS as another TLR agonist that is able to generate functional cross-priming against a soluble protein antigen. In addition, our results demonstrate that the ability of TLR stimuli to initiate CD8+ T-cell responses against soluble protein antigens is largely dependent on the IFN-alpha/beta signalling pathway.
authors.affiliation: The Edward Jenner Institute for Vaccine Research, Compton, Berkshire, UK.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Durand
authors.forename: Simon Yc
authors.initials: SY
authors.lastname: Wong
authors.forename: David F
authors.initials: DF
authors.lastname: Tough
authors.forename: Agnes
authors.initials: A
authors.lastname: Le Bon
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045142:Cross-Priming / Q000276:immunology; D007249:Inflammation / Q000276:immunology; D016898:Interferon-alpha / Q000097:blood / Q000276:immunology*; D016899:Interferon-beta / Q000097:blood / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000819:agonists* / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D011506:Proteins / Q000737:chemistry* / Q000276:immunology*; D011956:Receptors, Cell Surface / Q000819:agonists* / Q000276:immunology*; D015398:Signal Transduction; D012995:Solubility; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051199:Toll-Like Receptor 7; D051193:Toll-Like Receptors
chemical_list: D000906:Antibodies; D016898:Interferon-alpha; D008562:Membrane Glycoproteins; D011506:Proteins; D011956:Receptors, Cell Surface; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051199:Toll-Like Receptor 7; D051193:Toll-Like Receptors; D016899:Interferon-beta